查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984093

基因融合檢測市場：按技術、檢體類型、應用和最終用戶分類－2026-2032年全球市場預測

Gene Fusion Testing Market by Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因融合檢測市場價值將達到 3.2453 億美元，到 2026 年將成長至 3.4739 億美元，到 2032 年將達到 4.9739 億美元，複合年成長率為 6.28%。

主要市場統計數據
基準年 2025 3.2453億美元
預計年份：2026年 3.4739億美元
預測年份 2032 4.9739億美元
複合年成長率 (%) 6.28%

對基因融合檢測在診斷生態系統中的臨床路徑、轉化研究和相關人員決策中的重要性進行了簡潔且具有策略意義的概述。

基因融合檢測已成為現代分子診斷和轉化研究的關鍵要素，改變了腫瘤學、血液學和罕見疾病治療路徑中的臨床決策。檢測設計和分析流程的進步已將檢測方法從單基因和細胞遺傳學方法轉向整合分子譜分析，從而揭示可靶向的融合基因、抗藥性機制和疾病亞型。隨著標靶治療在臨床應用中的日益普及，準確識別基因融合對於患者篩選、治療監測以及合格醫療試驗的入組資格至關重要。

技術融合、監管澄清和臨床證據如何加速基因融合檢測在臨床環境中的標準化和更廣泛應用。

基因融合檢測領域經歷了變革性的轉變，這主要得益於技術融合、監管成熟和不斷湧現的臨床證據。細胞遺傳學檢測和單分析物檢測曾一度佔據主導地位，而如今，結合正交確證檢測和高解析度分析的多模態策略已成為主流。次世代定序加速了這一轉變，不僅擴大了已知和新型融合基因的檢測範圍，還使檢查室能夠整合工作流程，並縮短結果交付時間。

評估 2025 年美國關稅對基因融合檢測價值鏈的供應鏈、籌資策略和業務永續營運彈性的影響。

美國將於2025年實施的關稅政策，為基因融合檢測全球供應鏈中的相關人員帶來了新的挑戰。隨著成本結構的變化和供應風險評估的更新，採購團隊表示，試劑採購、設備購買和耗材供應管道都受到了更嚴格的審查。實驗室和製造商正在探索雙通路採購策略和庫存緩衝機制，以緩解短期供應波動，同時確保為患者提供持續的檢測服務。

針對特定細分市場的診斷和商業性見解，重點關注整個測試過程中的技術差異、檢體限制、臨床應用和最終用戶工作流程要求。

優先考慮基因融合檢測領域的投資和研發，需要深入了解特定片段的趨勢。在選擇技術時，必須考慮每種方法的獨特優勢和局限性，例如螢光原位雜合反應（FISH）、免疫組織化學、次世代定序和RT-PCR。此外，次世代定序本身也分為標靶panel定序、轉錄組定序和全基因測序等多種方法，每種方法在範圍、分析複雜性和基礎設施需求方面都存在差異。每種技術方法都需要不同的檢驗方法、生物資訊學流程和終端使用者培訓，以確保臨床層級的解讀和結果的可重複性。

影響各司法管轄區實施、夥伴關係模式和營運策略的區域比較趨勢：北美和南美、歐洲、中東和非洲以及亞太地區。

區域趨勢對基因融合檢測領域中相關人員的應用路徑、合作機會和營運重點有顯著影響。在美洲，服務提供模式由廣泛的診斷檢查室網路以及與臨床中心和藥物研發項目的高水準合作所塑造。該地區傾向於優先採用先進的定序技術，並建立與藥物研發時間表和法律規範相符的伴隨診斷。醫院、參考實驗室和產業合作夥伴之間的聯合聯盟通常能夠進行多中心檢驗研究，並加速臨床應用。

競爭格局分析著重於平台差異化、共同創新和策略夥伴關係，以推動臨床整合和市場滲透。

基因融合檢測領域的競爭格局呈現出多元化的特點，既有成熟的診斷公司，也有專業的定序平台供應商，還有專注於檢測化學和生物資訊學的新興創新者。領先的診斷開發公司正致力於打造端到端的解決方案，這些方案融合了檢驗的檢測方法、強大的資訊學功能、規範的文檔以及針對醫院和參考檢查室客戶量身定做的服務模式。平台提供者則透過提高通量、提升讀取準確性以及與實驗室資訊管理系統無縫整合來不斷提升自身競爭力，從而最大限度地減少工作流程中斷。

採取切實可行的策略行動，加強組織韌性，加快臨床部署，並透過與整個診斷和治療生態系統的合作來提高價值創造。

產業領導者應優先考慮一系列切實可行的舉措，以增強整個基因融合檢測生態系統的韌性，加速臨床部署，並創造新的價值。首先，投資於模組化、檢驗的工作流程，使檢查室能夠分階段引入基於定序的檢測方法，這將降低准入門檻，同時保持分析的嚴謹性。這種方法有助於逐步升級，減輕訓練負擔，從而促進醫院和獨立檢查室的更廣泛應用。

透明、多方面的研究途徑，結合相關人員訪談、技術文獻和案例研究，提供可操作的見解和建議。

本研究的綜合結果是基於一種多方面方法，旨在交叉檢驗技術、臨床和商業性觀點。主要資訊來源包括實驗室管理人員、分子病理學家、檢體採集管理人員和臨床試驗相關人員的結構化訪談，並輔以與檢測方法開發人員和平台提供者的直接諮詢。次要分析涵蓋了同行評審文獻、監管指導文件、技術白皮書和產品手冊，以檢驗分析方法和監管方面的考慮。在適用情況下，來自檢查室的匿名營運案例研究提供了有關工作流程實施和檢驗挑戰的真實世界背景。

綜合策略結論，旨在協調技術能力、營運韌性和合作夥伴關係關係，以最大限度地發揮基因融合檢測的臨床潛力。

基因融合檢測技術的成熟反映了技術創新、臨床需求以及診斷開發商、醫療系統和製藥合作夥伴之間策略合作的整合。隨著基於定序的方法日益普及和檢體處理技術的改進，將可靠的融合檢測整合到常規診斷中的機會比以往任何時候都更加清晰。然而，要實現這一潛力，需要對檢驗的工作流程、供應鏈韌性以及協作證據的生成進行規劃性投資，以證明其在不同患者群體中的臨床效用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：基因融合檢測市場：依技術分類

  • 螢光原位雜合反應
  • 免疫組織化學
  • 次世代定序
    • 標靶次世代定序
    • 轉錄組序列
    • 全基因組定序
  • 逆轉錄聚合酵素鏈鎖反應

第9章：依檢體類型分類的基因融合檢測市場

  • 血
    • 電漿
    • 血清
  • 組織
    • 福馬林固定石蠟包埋
    • 新鮮冷凍組織

第10章 基因融合檢測市場：依應用領域分類

  • 血液學
    • 白血病
    • 淋巴瘤
  • 腫瘤學
    • 乳癌
    • 結腸癌
    • 肺癌
    • 攝護腺癌
  • 罕見疾病
    • 發展障礙
    • 神經肌肉疾病

第11章 基因融合檢測市場：依最終用戶分類

  • 診斷檢測實驗室
    • 醫院檢查室
    • 獨立檢測實驗室
  • 醫院
    • 住院設施
    • 門診部
  • 製藥公司
    • 生技公司
    • 大型製藥企業
  • 研究機構
    • 學術研究機構
    • 私人研究機構

第12章 基因融合檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 基因融合檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 基因融合檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基因融合檢測市場

第16章：中國基因融合檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amoy Diagnostics Co., Ltd.
  • Arima Genomics, Inc.
  • Biocare Medical, LLC
  • Biocartis NV
  • Caris Life Sciences
  • Danaher Corporation
  • Empire Genomics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc.
  • OncoDNA SA
  • Paragon Genomics, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated.
  • SOPHiA GENETICS SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-2E76C3E47FBF

The Gene Fusion Testing Market was valued at USD 324.53 million in 2025 and is projected to grow to USD 347.39 million in 2026, with a CAGR of 6.28%, reaching USD 497.39 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 324.53 million
Estimated Year [2026] USD 347.39 million
Forecast Year [2032] USD 497.39 million
CAGR (%) 6.28%

Concise strategic framing of gene fusion testing relevance to clinical pathways, translational research, and stakeholder decision-making in diagnostic ecosystems

Gene fusion testing has emerged as a pivotal component of modern molecular diagnostics and translational research, reshaping clinical decision-making across oncology, hematology, and rare disease pathways. Advances in assay design and analytic pipelines have shifted testing from single-gene or cytogenetic approaches toward integrated molecular profiles that reveal actionable fusions, resistance mechanisms, and disease subtypes. As the clinical adoption of targeted therapies expands, precise identification of gene fusions has become essential for patient selection, therapeutic monitoring, and eligibility for precision medicine trials.

This summary synthesizes technological evolution, regulatory and trade influences, segment-level dynamics, regional adoption patterns, competitive movements, and recommendations for industry stakeholders. It draws on evidence of laboratory workflow optimization, the rising role of sequencing-based modalities, and the interplay between sample handling constraints and assay sensitivity. The goal is to provide decision-makers with a concentrated, strategically framed narrative that highlights where investment, partnership, and operational focus can materially improve clinical utility and commercial traction.

Throughout the document, emphasis is placed on how integrated testing strategies and cross-disciplinary collaboration between diagnostic laboratories, clinical centers, pharmaceutical developers, and research institutions are redefining pathways from discovery to clinical implementation. In doing so, readers will gain an actionable perspective on where scientific capability intersects with market and regulatory realities to create opportunities for innovation and competitive differentiation.

How technological convergence, regulatory clarity, and clinical evidence are accelerating standardization and broader clinical adoption of gene fusion testing

The landscape for gene fusion testing has undergone transformative shifts driven by technological convergence, regulatory maturation, and evolving clinical evidence. Historically dominated by cytogenetic and single-analyte assays, the field now favors multi-modal strategies that combine orthogonal confirmation with high-resolution profiling. Next-generation sequencing has catalyzed this transition, enabling broader detection of canonical and novel fusions while allowing laboratories to consolidate workflows and reduce time-to-result variability.

Concurrently, the clinical utility of fusion detection has expanded beyond initial diagnostic categorization to include therapy selection, minimal residual disease evaluation, and companion diagnostic development. This evolution is complemented by improvements in sample processing, such as enhanced nucleic acid extraction from formalin-fixed paraffin embedded tissue and optimized plasma protocols for circulating nucleic acids, which collectively increase assay yield and broaden patient eligibility for noninvasive testing.

Market access drivers, including more nuanced reimbursement frameworks and clearer regulatory pathways for laboratory-developed tests and in vitro diagnostics, have supported the adoption of advanced assays in hospital-based and independent laboratories alike. Partnerships between diagnostic developers and pharmaceutical companies have also intensified as drug development increasingly predicates enrollment on molecularly defined populations. Taken together, these shifts indicate a maturing ecosystem where technological capability, clinical need, and commercial incentives align to accelerate the standardization and scaling of gene fusion testing.

Assessment of the 2025 United States tariff impacts on supply chains, procurement strategies, and operational resilience within gene fusion testing value chains

The introduction of United States tariffs in 2025 has created a new layer of complexity for stakeholders operating in global supply chains for gene fusion testing. Procurement teams report increased scrutiny of reagent sourcing, instrument purchases, and consumable pipelines as cost profiles shift and supply risk assessments are updated. Laboratories and manufacturers are evaluating dual-sourcing strategies and inventory buffers to mitigate near-term procurement volatility while maintaining continuity of testing services for patients.

Beyond procurement, the tariff environment has prompted strategic re-evaluation of regional manufacturing footprints and distribution networks. Some companies have accelerated localization of critical component manufacturing or pursued partnerships with domestic suppliers to reduce exposure to cross-border duties. Regulatory teams are also anticipating potential product requalification needs associated with component substitutions, driving closer collaboration between quality assurance, regulatory affairs, and supply chain functions.

Clinicians and laboratory directors emphasize that maintaining assay performance and turnaround times remains paramount; therefore, operational adjustments prioritize validated alternatives and compatibility testing to avoid disruptions to clinical workflows. In parallel, commercial teams are recalibrating pricing and contracting models with health systems and reference laboratories to absorb or pass through cost impacts based on customer negotiations and competitive dynamics. Overall, the tariff-driven environment is forcing a more resilient and flexible industry posture, with an emphasis on supply chain transparency, localized capabilities, and cross-functional coordination to sustain uninterrupted patient care.

Segment-focused diagnostic and commercial insights highlighting technology distinctions, sample constraints, clinical applications, and end-user workflow requirements across the testing continuum

A granular appreciation of segment-specific dynamics is essential for targeting investment and development priorities within the gene fusion testing domain. When examining technology, assessments need to reflect the distinct advantages and constraints of Fluorescence In Situ Hybridization, Immunohistochemistry, Next Generation Sequencing, and RT-PCR, noting that Next Generation Sequencing itself comprises targeted panels, transcriptome sequencing, and whole genome sequencing approaches that vary in breadth, analytical complexity, and infrastructure requirements. Each technological path demands different validation approaches, bioinformatics pipelines, and end-user training to ensure clinical-grade interpretation and reproducibility.

Sample type considerations strongly influence operational design and test accessibility. Blood-based workflows require protocols for plasma and serum processing that preserve circulating nucleic acids, while tissue workflows must account for formalin-fixed paraffin embedded specimens and fresh frozen tissue, each presenting trade-offs in nucleic acid integrity, turnaround, and histopathology integration. Application-driven segmentation highlights that hematology, oncology, and rare disease use cases impose divergent clinical thresholds for sensitivity, specificity, and reporting granularity. Within hematology, testing for leukemia and lymphoma informs therapeutic stratification and minimal residual disease assessment, whereas oncology applications in breast, colorectal, lung, and prostate cancers prioritize the detection of actionable fusions and mechanisms of resistance. Rare disease applications, including developmental disorders and neuromuscular conditions, often require broader transcriptomic interrogation and specialized interpretation frameworks.

End-user differentiation further shapes commercial approaches and service design. Diagnostic laboratories, both hospital-based and independent, emphasize throughput optimization and assay standardization; hospitals, across inpatient facilities and outpatient clinics, value rapid turnaround and integration with electronic health records; pharmaceutical companies, spanning biotechnology firms and larger pharma organizations, seek companion diagnostic partnerships and rigorous analytical validation to support clinical trials; and research institutions, including academic centers and private research laboratories, drive early-stage discovery and method development that can translate into clinical pipelines. Understanding these interconnected segments enables more precise prioritization of product features, go-to-market channels, and collaborative models that align technical capability with end-user workflows and interpretive needs.

Comparative regional dynamics that shape adoption, partnership models, and operational strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific jurisdictions

Regional dynamics materially influence adoption pathways, partnership opportunities, and operational priorities for gene fusion testing stakeholders. In the Americas, service delivery models are shaped by an extensive network of diagnostic laboratories and a high degree of integration between clinical centers and pharmaceutical development programs. This region tends to prioritize rapid implementation of advanced sequencing modalities and the establishment of companion diagnostics that align with drug development timelines and regulatory frameworks. Collaborative consortia between hospitals, reference labs, and industry partners frequently enable multi-site validation studies and accelerated clinical adoption.

In Europe, Middle East & Africa, the landscape is heterogeneous, with pockets of highly centralized national reference laboratory systems coexisting alongside decentralized hospital networks. Regulatory harmonization efforts and cross-border clinical collaborations are driving wider adoption in select markets, while health system procurement models and reimbursement pathways vary significantly. Stakeholders in this region often focus on demonstrating cost-effectiveness, clinical utility, and interoperability with diverse health IT infrastructures to gain adoption across public and private providers.

Across Asia-Pacific, rapid infrastructure investment and strong government support for precision medicine initiatives have catalyzed growth in both academic research and commercial testing capacity. Laboratories in several markets are scaling sequencing-based services and developing localized manufacturing capabilities to reduce reliance on imports. Regional public health priorities and population-specific genomic characteristics also shape test selection and assay validation strategies, prompting tailored approaches that reflect local clinical needs and sample availability. These regional nuances necessitate differentiated engagement models and strategic investment plans to optimize market entry, partnerships, and service delivery.

Competitive landscape analysis emphasizing platform differentiation, collaborative innovation, and strategic partnerships that drive clinical integration and market traction

Competitive activity in the gene fusion testing arena is defined by a mix of established diagnostic companies, specialized sequencing platform providers, and emerging innovators focused on assay chemistry and bioinformatics. Leading diagnostic developers are investing in end-to-end solutions that combine validated assays with robust informatics, regulatory documentation, and service models tailored to hospital and reference laboratory customers. Platform providers continue to differentiate through throughput capabilities, read accuracy, and seamless integration with laboratory information management systems to minimize workflow interruption.

At the same time, innovative entrants are pushing the boundaries of sensitivity and breadth through transcriptome-level approaches and novel library preparation chemistries that enable detection of complex or rare fusion events. These advancements often emerge from academic collaborations and private research labs before being adopted in clinical settings, underscoring the importance of strategic partnerships between research institutions and commercial entities. Pharmaceutical companies remain key collaborators, commissioning analytical validation studies and co-developing companion diagnostics to support targeted therapy programs.

Mergers, strategic alliances, and distribution agreements are common mechanisms for scaling global presence and addressing supply chain vulnerabilities. Companies that successfully combine strong technical platforms, validated clinical utility, and flexible commercial models are better positioned to secure long-term relationships with health systems and trial sponsors. Ultimately, competitive advantage accrues to organizations that balance innovation with regulatory rigor, operational reliability, and clear evidence of clinical impact.

Practical strategic actions for organizations to enhance resilience, accelerate clinical adoption, and strengthen collaborative value creation across diagnostic and therapeutic ecosystems

Industry leaders should prioritize a series of actionable initiatives to strengthen resilience, accelerate clinical adoption, and unlock new value across the gene fusion testing ecosystem. First, investing in modular, validated workflows that allow laboratories to adopt sequencing-based assays incrementally can lower barriers to entry while preserving analytical rigor. This approach facilitates stepwise upgrades and reduces training friction, enabling broader uptake among hospital-based and independent laboratories.

Second, strengthening supply chain transparency and diversifying sourcing strategies will mitigate tariff and disruption risks. Establishing qualified secondary suppliers for critical reagents and exploring regional manufacturing partnerships can minimize lead-time variability and protect assay continuity. Parallel to procurement strategies, stakeholders should institute robust change-control protocols that preemptively qualify alternative components without compromising performance.

Third, companies should deepen collaborations with pharmaceutical developers and clinical networks to co-develop companion diagnostics and prospective validation studies that demonstrate clinical utility. Aligning assay design with therapeutic development pipelines can accelerate patient access to targeted therapies and enhance the commercial value proposition. Finally, investing in clinician-facing education and standardized reporting templates will improve test interpretation, increase clinician confidence, and facilitate smoother integration into treatment decision pathways. These combined actions will position organizations to respond nimbly to external shocks while capturing opportunities created by technological innovation and evolving clinical demand.

Transparent multi-method research approach combining stakeholder interviews, technical literature, and operational case studies to underpin actionable insights and recommendations

This research synthesis is grounded in a multi-method approach designed to triangulate technical, clinical, and commercial perspectives. Primary inputs include structured interviews with laboratory directors, molecular pathologists, procurement leads, and clinical trial stakeholders, complemented by direct consultation with assay developers and platform providers. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, technical whitepapers, and product manuals to validate analytical approaches and regulatory considerations. Where applicable, anonymized operational case studies from laboratories provided real-world context on workflow implementation and validation challenges.

Analytical rigor was maintained through methodical cross-validation of technology performance characteristics, sample handling protocols, and end-user requirements. The methodology prioritized peer-reviewed evidence and primary stakeholder testimony to ensure recommendations reflect both scientific validity and operational feasibility. Sensitivity to regional regulatory and reimbursement environments informed the regional insights, while supply chain assessments integrated procurement data and supplier interviews to evaluate vulnerability and mitigation options.

Limitations inherent to any synthesis are acknowledged, including variability in reporting standards across laboratories and differences in local regulatory interpretation. To address these constraints, the methodology emphasizes transparency in data sources, explicit documentation of assumptions, and the provision of methodological appendices that detail interview guides, inclusion criteria, and validation checkpoints. This approach enables stakeholders to adapt findings to their specific operational contexts with confidence in the underlying evidence base.

Integrated strategic conclusions on aligning technical capability, operational resilience, and collaborative partnerships to realize the full clinical potential of gene fusion testing

The maturation of gene fusion testing reflects a convergence of technological innovation, clinical necessity, and strategic alignment among diagnostic developers, health systems, and pharmaceutical partners. As sequencing-based approaches become more accessible and sample processing improves, the opportunity to embed robust fusion detection into routine diagnostics has never been clearer. However, realizing that potential requires deliberate investments in validated workflows, supply chain resilience, and collaborative evidence generation that demonstrates clinical utility across diverse patient populations.

Stakeholders that act now to align assay design with end-user workflows, diversify supply networks, and engage in strategic partnerships with therapy developers will be best positioned to capitalize on scientific advances while safeguarding operational continuity. The evolving regulatory and reimbursement landscape rewards clarity of evidence and cross-sector collaboration, making early engagement with clinical and regulatory stakeholders a competitive differentiator. In conclusion, the gene fusion testing ecosystem is poised for sustained clinical integration, and organizations that pursue coordinated technical, commercial, and operational strategies will lead the next phase of translation from discovery to improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Fusion Testing Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Immunohistochemistry
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Next Generation Sequencing
    • 8.3.2. Transcriptome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Reverse Transcription Polymerase Chain Reaction

9. Gene Fusion Testing Market, by Sample Type

  • 9.1. Blood
    • 9.1.1. Plasma
    • 9.1.2. Serum
  • 9.2. Tissue
    • 9.2.1. Formalin Fixed Paraffin Embedded
    • 9.2.2. Fresh Frozen Tissue

10. Gene Fusion Testing Market, by Application

  • 10.1. Hematology
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
  • 10.2. Oncology
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Prostate Cancer
  • 10.3. Rare Diseases
    • 10.3.1. Developmental Disorders
    • 10.3.2. Neuromuscular Disorders

11. Gene Fusion Testing Market, by End User

  • 11.1. Diagnostic Laboratories
    • 11.1.1. Hospital Based Laboratories
    • 11.1.2. Independent Laboratories
  • 11.2. Hospitals
    • 11.2.1. Inpatient Facilities
    • 11.2.2. Outpatient Clinics
  • 11.3. Pharmaceutical Companies
    • 11.3.1. Biotechnology Companies
    • 11.3.2. Pharma Giants
  • 11.4. Research Institutions
    • 11.4.1. Academic Centers
    • 11.4.2. Private Research Laboratories

12. Gene Fusion Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Fusion Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Fusion Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Gene Fusion Testing Market

16. China Gene Fusion Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amoy Diagnostics Co., Ltd.
  • 17.6. Arima Genomics, Inc.
  • 17.7. Biocare Medical, LLC
  • 17.8. Biocartis NV
  • 17.9. Caris Life Sciences
  • 17.10. Danaher Corporation
  • 17.11. Empire Genomics, Inc.
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. Guardant Health, Inc.
  • 17.14. Illumina, Inc.
  • 17.15. Integrated DNA Technologies, Inc.
  • 17.16. Myriad Genetics, Inc.
  • 17.17. Natera, Inc.
  • 17.18. NeoGenomics, Inc.
  • 17.19. OncoDNA SA
  • 17.20. Paragon Genomics, Inc.
  • 17.21. QIAGEN N.V.
  • 17.22. Quest Diagnostics Incorporated.
  • 17.23. SOPHiA GENETICS SA
  • 17.24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENE FUSION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENE FUSION TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENE FUSION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. GCC GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. GCC GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 264. GCC GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 266. GCC GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 267. GCC GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. GCC GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. GCC GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. GCC GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. GCC GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GCC GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 273. GCC GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 275. GCC GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 306. G7 GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. G7 GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. G7 GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 309. G7 GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. G7 GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 311. G7 GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 312. G7 GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. G7 GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. G7 GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. G7 GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 316. G7 GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. G7 GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 318. G7 GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 319. G7 GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 320. G7 GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 321. NATO GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. NATO GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. NATO GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 324. NATO GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. NATO GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 326. NATO GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 327. NATO GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 328. NATO GE